

BDR Pharma launches gastric cancer drug FURMECIL

20 April 2022 | News

The drug will be launched in the form of capsules in two strengths



Mumbai-based BDR Pharmaceuticals has launched oral drug FURMECIL, a combination of three drugs - Tegafur, Gimeracil and Oteracil (also known as S-1) to treat advanced gastric cancer.

Furmecil is soon going to be available in the Indian market, in the form of capsules in two strengths (Tegafur 15 mg + Gimeracil 4.35 mg + Oteracil 11.80 mg & Tegafur 20 mg + Gimeracil 5.80 mg + Oteracil 15.80 mg).

Commenting on the launch, Raheel Shah, Director Business Development on behalf of BDR Pharmaceuticals said, "Our focused launch of such first time ever newly advanced molecule in treatment of various cancer indications, is testimony to our solid commitment to providing access to affordable medicines for Indian cancer patients with high quality standards without compromising patient's safety".

Gastric cancer remains one of the most important malignancies worldwide in terms of incidence and mortality. It is the fourth most common malignant disease and the second leading cause of cancer-related deaths worldwide. The treatment consists of targeted molecules, a combination of local surgery and radiation therapy as well as systemic chemotherapy. The combination therapy with S-1 has been in progress to obtain a better survival benefit, lower cost and better quality of life as per Indian Journal of Medical and Paediatric Oncology.